Evaluation of the effect of duration of diabetes mellitus on peripheral neuropathy using the United Kingdom Screening Test Scoring System, Bio-thesiometry and Aesthesiometry

Nigerian Journal of Clinical Practice

Volumn 13, Issue 3, 2010, Pages 240-247

  Oguejiofor, O C ^a   Odenigbo, C U ^a   Oguejiofor, C B N ^a  

^a NNAMDI AZIKIWE UNIVERSITY   (Nigeria)

Author keywords

Aesthesiometry; Biothesiometry; Diabetic foot ulceration; Peripheral neuropathy; United Kingdom Screening Test

Indexed keywords

ADULT; AGED; ARTICLE; DIABETIC FOOT; DIABETIC NEUROPATHY; EVALUATION; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; NIGERIA; PERCEPTIVE THRESHOLD; PHYSIOLOGY; RISK FACTOR; TIME; TOUCH; VIBRATION;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC FOOT; DIABETIC NEUROPATHIES; HUMANS; MALE; MIDDLE AGED; NIGERIA; RISK FACTORS; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOUCH PERCEPTION; VIBRATION;

EID: 77956665238     PISSN: 11193077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Lavery LA, Armstrong DG, Velsa SA, Quebedeaux TL, Fleischli JG Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med 1998; 158:157-162.
2. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15:815-819.
3. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG Risk factors for diabetic peripheral sensory neuropathy. Diabetes Care 1997;20:1162-1167.
4. Bild DE, Selby JV, Sinnock P. Lower extremity amputation in people with diabetes: Epidemiology and prevention. Diabetes Care 1989;12:24-31.
5. Walter DP, Gatling W, Mulle MA, Hill RD. The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group. Diabetic Medicine 1992; 9:354-358.
6. Jones RB, Gregory R, Jones EW. The quality and relevance of peripheral neuropathy data on a' diabetic clinical information system. Diabetic Medicine 1992;9:934-937.
7. Walter DP, Gatling W, Mulle MA, Hill RD. The prevalence of diabetic sensory neuropathy in an English community. Diabetic Medicine 1992; 9:349-353.
8. Akanji AO, Famuyiwa OO, Adetuyibi A. Factors influencing the outcome of treatment of foot lesions in Nigerian patients with diabetes mellitus. QJM 1989;73:1005-1014.
9. Maser RE, Steenkiste AR, Dorman JS. Epidemiology correlates of diabetic neuropathy. Reports from Pittsburgh epidemiology of diabetes complication study. Diabetes 1989; 38:1456-1461.
10. Dyck PJ. Peripheral neuropathy: new concepts and therapy. Neurol Clin 1992; 10:3-6.
11. Brownlee MA, King GL. Chronic complications of diabetes. Endocrinol Metab Clin North Am 1996; 25(2): 336-337.
12. Tomlinson DR. Polyols and myoinositol in diabetic neuropathy of mice and men. MAYO Clin P 1989;64:1030-1033.
13. Malik RA, Nuerick PG, Sharma AK. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989; 32: 92-102.
14. Llewelyn JG, Thomas PK, Gilbey SG, Watkins PJ, Muddle JR. Pattern of myelinated fibre loss in the sural nerve in neuropathy related to type 1 (insulin-dependent) diabetes. Diabetologia 1988; 31:162-167.
15. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990; 81:402-406.
16. Zanone MM, Banga JP, Peakman M, Edmonds M, Watkins PJ. An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. Diabet Med 1994; 11:378-383.
17. Harati Y. Diabetic peripheral neuropathies. Ann Intern Med 1987; 107:546-559.
18. Guy RJC, Clarke CA, Malcolm PN, Watkins PJ. Evaluation of thermal and vibration sensation in diabetic neuropathy. Diabetologia 1985; 28: 131-137.
19. Okuyama M, Nagai K, Miyazaki S, Kosaka J, Kamikubo K, Miura K et al. Diabetic gangrene in Japan: analysis of487 cases. Tohoku J Exp Med 1983;141:583-586.
20. Deanfield JE, Dagget PR, Harrison MJC. The role of autonomic neuropathy in diabetic foot ulceration. J Neurol Sci 1980; 47:203-210.
21. Ryder REJ, Kennedy RL, Newrick PG. Autonomic denervation may be a prerequisite of diabetic neuropathic foot ulceration. Diabet Med 1990;7:726-730.
22. Edmonds ME, Nicolaides KH, Watkins PJ. Autonomic neuropathy and diabetic foot ulceration. Diabet Med 1986; 3:56-59.
23. Ahmed ME, Delbridge L, Le Quesne LP. The role of autonomic neuropathy in diabetic foot ulceration. J Neurol Neurosurg Psychiatry 1986; 49:1002-1006.
24. Franklin GM, Kahn LB, Baxter J. Sensory neuropathy in non-insulin dependent diabetes mellitus: The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131:633-643.
25. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1. Report of a WHO Consultation. WHO Geneva, 1999.
26. Young MJ, Boulton AJM, Macleod AF. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150-154.
27. Linger C, Albeanu A, Bloise D. The tuning fork revisited. Diabet Med 1990; 7:859-864.
28. Van Deursen RWM, Sanchez MM, Derr JA, Becker MB, Ulbrecht JS, Cavanagh PR. Vibration perception threshold testing in patients with diabetic neuropathy: ceiling effects and reliability. Diabetic Medicine 2001, 18:469-475.
29. Boulton AJM, Betts RP, Franks CI, Newrick PG, Ward JD, Duckworth T. Abnormalities of foot pressure in early diabetic neuropathy. Diabet Med 1987;4:225-228.
30. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. Diabetes Care 1994; 17:557-560.
31. Boulton AJ. The diabetic foot. In: Diabetes Clinical Management. Tattersall RB, Gale E A (eds). Churchill Livingstone, Edinburgh 1990; pp 293-310.
32. Connecticut Bio-instruments Inc. WEST tm: Nerve tester for the foot. Http://www.cbi-pace.com/cbi.htm.
33. Sosenko JM, Kato M, Soto R, Bild DE. Comparison of quantitative sensory threshold measures for their association with foot ulceration in diabetic patients. Diabetic Care 1990; 13:1057-1061.
34. The International Working Group on the Diabetic Foot. International Consensus of the diabetic foot. Foot. Amsterdam, 1999; 1-96.
35. Ogbera AO, Ohwovoriole AE. The prevalence of the "foot- at risk " for ulceration in diabetic patients in an urban hospital. African Journal of Endocrinology and Metabolism 2003; 4(1): 35-39.
36. Ogbera AO, Ohwovoriole AE. The economic costs of diabetes mellitus foot syndrome. African Journal of Endocrinology and Metabolism 2003;4(1): 59-63.
37. Benbow S, Gill G Diabetic foot ulceration in developed and developing countries. International Diabetes Digest 1998; 8:8-10.
38. Dagogo-Jack S. Pattern of diabetes foot ulcer in Port Harcourt Nigeria. Pract Diab Digest 1991; 2:75-80.
39. de-Sonnaiville JJ, Coliig LP, Wijkel D, Heine RJ. The prevalence and determinants of foot ulceration in type II diabetic patients in a primary health care setting. Diabetes Research and Clinical Practice 1997;35:149-156.
40. Caputo GM, Joshi N, Weitekamp MR. Foot infections in patients with diabetes. American Family Physician 1997; 56:195-202.
41. Belmin J, Valensi P. Diabetic neuropathy in elderly patients: What can be done? Drugs Aging 1996;8:416-429.
42. Trautner C, Haastert B. Incidence of lower limb amputations and diabetes. Diabetes Care 1996; 19: 1006-1009.